ANGIODYNAMICS INC — Form 8-K
Filed October 8, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
AngioDynamics reported Q1 FY2027 (ended Aug 31, 2026) net sales of $80.9M (+6.9% YoY), with Med Tech segment growing 13.2% to $39.9M and Med Device flat at 1.4% growth to $41.0M. The company posted GAAP net loss of $7.1M ($0.17 per share) and adjusted EBITDA of $5.0M. Leadership transition: Eric Honroth appointed President and CEO effective Nov 2, 2026, succeeding Jim Clemmer after 10 years. Company reiterated full-year FY2027 guidance of $336-341M revenue, 12-15% Med Tech growth, and $13-16M adjusted EBITDA. FDA approved the RELIEF study for NanoKnife IRE in benign prostatic hyperplasia.
Why this rating
Solid quarterly execution (Med Tech +13.2%, adjusted EBITDA +127% YoY) against $436M market cap is positive, but CEO transition creates near-term uncertainty. Company remains unprofitable on GAAP basis. Modest 6.9% total growth and flat Med Device segment temper optimism. Guidance reiteration suggests confidence but no new catalysts announced. Event is meaningful but not trajectory-altering.
See more from October 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.